Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 16,851 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: HIV
Interventions: MRI, L-NMMA, Acetylcholine; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Coronary Syndrome
Interventions: Educational/Counseling/Training; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 19 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 5
States / cities: Flint, Michigan • Saginaw, Michigan

Conditions: HIV Infections
Interventions: Directly observed therapy (DOT); Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more

Conditions: Down Syndrome, Cognitive Dysfunction
Interventions: Aricept (Donepezil hydrochloride), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 6 Years to 10 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: San Antonio, Texas • Herndon, Virginia

Conditions: LGMD1B, LGMD1C, LGMD1D, LGMD1E, LGMD1F, LGMD1G, LGMD1H, LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E, LGMD2F, LGMD2G, LGMD2I, LGMD2J, LGMD2K, LGMD2L, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2Q, LGMD2S, LGMD2T, LGMD2U, LGMD2W, LGMD2X, LGMD2Y
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 6 Years to 50 Years
Enrollment: 1,000 participants
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Respiratory Distress Syndrome
Interventions: Poractant alfa, calfactant; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Weeks to 35 Weeks
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: HIV Infections
Interventions: Lymphocytes, Activated; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cyclosporine, irinotecan hydrochloride, phenobarbital; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epilepsy, Epilepsy, Temporal Lobe, Depression, Depressive Disorder, Major
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions: Elinzanetant (BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myelodysplastic Syndrome
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 12
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 6 more

Conditions: HIV Infections
Interventions: Short Cycle Antiretroviral Therapy; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Prednisone; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ocular Histoplasmosis Syndrome
Interventions: ranibizumab; Drug
Lead sponsor: Retina Associates of Kentucky; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: 5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution; Drug · Other
Lead sponsor: Mimetogen Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Glendale, California • Murrieta, California + 25 more

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Doravirine, 2 NRTIs, DOR/3TC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 4 Weeks to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions: Computer Tablet Group, Paper and Pencil Group, Contact Control Group; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 76 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cyclic Vomiting Syndrome
Interventions: The Bridge device; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
Interventions: anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Phoenix, Arizona • Duarte, California

Conditions: Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 22 Years
Enrollment: 255 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Morquio Syndrome A, Maroteaux Lamy Syndrome, MPS IVA, MPS VI
Interventions: Not listed
Lead sponsor: Greenwood Genetic Center; Other
Eligibility: Up to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Greenville, South Carolina

Search by objective public record fields.

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

Translating Research: Patient Decision Support/Coaching

Directly Observed Therapy for HIV Infected Adolescents

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Long-Term Development of Muscular Dystrophy Outcome Assessments

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Three Dosing Schedules of Oral Rigosertib in MDS Patients

An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

Drug Interaction Study Between Dolutegravir and Prednisone

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

e-Mobile Tablet for People With Chronic Conditions

Effectiveness of Electrical Neurostimulation in Cyclic Vomiting Syndrome.

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome